Recent Finacing
Recent Raise
Axoltis Pharma is a French biotech developing NX210c, a peptide therapy that restores the blood–brain barrier for amyotrophic lateral sclerosis (ALS) and other neurological disorders.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Axoltis Pharma.
